NCT02524717 is a Phase 1 clinical trial of JNJ-56021927 in Hepatic Impairment, sponsored by Aragon Pharmaceuticals, Inc..

Who is sponsoring NCT02524717?

NCT02524717 is sponsored by Aragon Pharmaceuticals, Inc..

What drugs are being tested in NCT02524717?

Interventions in NCT02524717: JNJ-56021927.

What condition does NCT02524717 study?

NCT02524717 studies Hepatic Impairment.

Is NCT02524717 still recruiting?

NCT02524717 is currently completed. Last updated 3 February 2025.

Last reviewed 2025-02-03 · How we verify

NCT02524717

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Completed Phase 1 Last updated 3 February 2025

What this trial tests

Phase 1 trial testing JNJ-56021927 in Hepatic Impairment in 24 participants. Completed in 9 February 2017.

Timeline

13 August 2015

Primary endpoint
9 February 2017

9 February 2017

Quick facts

Lead sponsor	Aragon Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	13 August 2015
Primary completion	9 February 2017
Estimated completion	9 February 2017
Sites	2 locations across United States

Drugs / interventions tested

JNJ-56021927

Conditions studied

Hepatic Impairment — all drugs for Hepatic Impairment →

Sponsor

Aragon Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 80, male only, with Hepatic Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to characterize the pharmacokinetics of JNJ-56021927 in participants with mild and moderate hepatic impairment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of JNJ-56021927

Trials testing the same drug.

NCT02123758 — A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate · Phase 1 · active not recruiting
NCT02162836 — A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer · Phase 1 · completed

Other recruiting trials for Hepatic Impairment

Currently open trials in the same condition.

NCT07269301 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function · Phase 1 · recruiting
NCT07219550 — A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) · Phase 1 · recruiting
NCT07144111 — A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib · Phase 1 · recruiting
NCT07023354 — A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems · Phase 1 · recruiting
NCT06985615 — A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement · Phase 1 · recruiting

Other Aragon Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT02592317 — A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and · Phase 1 · active not recruiting
NCT02578797 — A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study · Phase 1 · completed
NCT02489318 — A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With m · Phase 3 · active not recruiting
NCT02531516 — An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radia · Phase 3 · active not recruiting
NCT02257736 — An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02524717 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aragon Pharmaceuticals, Inc.
Last refreshed: 3 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02524717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing